106 related articles for article (PubMed ID: 25638543)
21. Pertuzumab plus trastuzumab in metastatic breast cancer.
Revannasiddaiah S; Seam R; Gupta M
N Engl J Med; 2012 Apr; 366(14):1349; author reply 1349-50. PubMed ID: 22475604
[No Abstract] [Full Text] [Related]
22. Pertuzumab plus trastuzumab in metastatic breast cancer.
Li-Wan-Po A
N Engl J Med; 2012 Apr; 366(14):1348-9; author reply 1349-50. PubMed ID: 22475603
[No Abstract] [Full Text] [Related]
23. Pertuzumab plus trastuzumab in metastatic breast cancer.
Şendur MA; Aksoy S; Zengin N
N Engl J Med; 2012 Apr; 366(14):1348; author reply 1349-50. PubMed ID: 22475602
[No Abstract] [Full Text] [Related]
24. Breast cancer: CLEOPATRA sheds light on how to tackle metastatic disease.
Errico A
Nat Rev Clin Oncol; 2015 Apr; 12(4):188. PubMed ID: 25734635
[No Abstract] [Full Text] [Related]
25. Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon.
Fink MK; Kleeberg UR; Bartels S
Oncologist; 2015 Jan; 20(1):88. PubMed ID: 25589500
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.
Fink MK; Kleeberg UR; Bartels S
Oncologist; 2015 Jul; 20(7):e23. PubMed ID: 26069279
[TBL] [Abstract][Full Text] [Related]
27. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab emtansine in breast cancer.
Dirix LY; Rutten A; Huget P; Dirix M
Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
[TBL] [Abstract][Full Text] [Related]
29. Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Truchuelo M; Vano-Galvan S; Pérez B; Muñoz-Zato E; Jaén P
Dermatol Online J; 2009 Mar; 15(3):7. PubMed ID: 19379651
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib plus capecitabine in breast cancer.
Sonpavde G
N Engl J Med; 2007 Apr; 356(14):1471; author reply 1471-2. PubMed ID: 17409332
[No Abstract] [Full Text] [Related]
31. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
[TBL] [Abstract][Full Text] [Related]
32. New treatment strategies provide more options for patients with breast cancer.
Hampton T
JAMA; 2008 Jul; 300(4):381-2. PubMed ID: 18647973
[No Abstract] [Full Text] [Related]
33. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Cameron D
Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
[No Abstract] [Full Text] [Related]
34. Drug combination approved for advanced breast cancer.
FDA Consum; 2002; 36(1):5. PubMed ID: 11881602
[No Abstract] [Full Text] [Related]
35. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bisagni G; Musolino A; Panebianco M; De Matteis A; Nuzzo F; Ardizzoni A; Gori S; Gamucci T; Passalacqua R; Gnoni R; Moretti G; Boni C
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1051-7. PubMed ID: 23377310
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
37. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
38. NICE recommends new treatment for breast and bowel cancer.
Mayor S
BMJ; 2003 May; 326(7400):1166. PubMed ID: 12775610
[No Abstract] [Full Text] [Related]
39. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
40. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
Galligioni E
Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
